Rare disease treatment industry from the biologics segment reached USD 166.9 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its several benefits, such as, high specificity, low toxicity, extreme sensitivity to physical conditions, etc. Read More